Clinical Study to Evaluate Clinical Outcomes of LuxSmart IOL as Compared With LuxGood IOL

N/AActive Not RecruitingNCT06105190

Cutting Edge SAS251 enrolled

Overview

This study is a multicentric, prospective, randomised, controlled, post-market clinical follow up (PMCF) study to investigate safety, visual outcomes and contrast sensitivity after bilateral implantation of either LuxSmart IOLs (study group) or LuxGood IOLs (control group).

This study is a multicentric, prospective, randomised, controlled, post-market clinical follow up (PMCF) study whereby subjects undergoing routine cataract surgery will have bilateral implantation of either LuxSmart IOLs (study group) or LuxGood IOLs (control group). The subjects will be randomized in a 1:1 ratio to receive the study or control lenses. Both study and control IOLs, are CE approved The study and control IOLs, and all devices used for the study examinations, will be used within the intended use specifications from the manufacturer. In addition, no invasive or other burdening examinations will occur for the subject. The study device (LuxSmart) is a hydrophobic, premium monofocal intraocular lens (IOL) manufactured by the sponsor of this study. The control lens (LuxGood) is the monofocal parent lens sharing the same material and optic design but with slight differences in the optic design. The IOLs will be implanted as part of the routine cataract surgery on subjects suffering from cataract. The targeted study cohort represents the standard subject cohort for cataract surgery. In total 238 subjects will be enrolled for this clinical study and receive bilateral implantation of the study or control lens based on a 1:1 randomization given by the EDC. Subjects participating in the trial will attend a total of 6 to 10 study visits (1 preoperative, 1 or 2 operative and 4 - 7 postoperative visits that may be carried out at the same day if requirements allow) over a period of 6 months. Data analyses will be performed after the last patient finished the 120-180 days postoperative examination.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

251

Conditions

Cataract Lens Opacities

Interventions

Implantation of premium monofocal IOL, LuxSmart (device under investigation)DEVICE

Patients will be implanted with study IOL in both eyes

Implantation of monofocal IOL, LuxGood (control device)DEVICE

Patients will be implanted with Control IOL in both eyes

Eligibility

Sex: ALLMin age: 22 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Clinically documented age-related cataracts in both eyes; 2. Calculated IOL power performed using an optical biometer is within the range of the study and control IOLs (15D to 28D); 3. Male or female adults aged 22 years or older on the day of first-eye surgery; 4. Regular corneal astigmatism ≤ 1.0 D (measured by IOL Master) in both eyes; 5. Clear intraocular media other than cataract in both eyes; 6. Willing and able to comply to the study requirements; 7. Capability to understand and sign an IRB approved informed consent form and privacy authorization; 8. Monocular best corrected visual acuity projected to be ≤ 0.18 logMAR (≥ 20/30 in Snellen) after IOL implantation in both eyes; 9. Subjects must have discontinued use of contact lenses for at least two weeks (for hard or toric lenses) or 3 days (for soft non-toric contact lenses) prior to the pre-operative examination, and throughout the clinical study; 10. Current contact lens wearers must demonstrate a stable refraction (within ±0.5 D for both sphere and cylinder) in each eye, as determined by distance manifest refraction on two consecutive examination dates after discontinuation of contact lens wear; Exclusion Criteria: 1. Regular corneal astigmatism \>1.0 D (measured by IOL Master) in one or both eyes; 2. Irregular astigmatism (measured by a topographer) in both eyes; 3. Difficulties for cooperation; 4. Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal or optic disorders) that are predicted to cause future acuity loss to 20/30 or worse in one or both eyes; 5. Subjects with AMD suspicious eyes as determined by OCT examination; 6. Previous intraocular or corneal surgery in one or both eyes; 7. Traumatic cataract in one or both eyes as judged by investigator; 8. History or presence of macular edema in one or both eyes; 9. Instability of keratometry or biometry measurements; Acceptable maximum standard deviation: AL: ± 150 µm; ACD: ± 150 µm; K1 / K2: ± 0.15 D in both eyes; 10. Clinically significant, uncontrolled glaucoma with expected negative impact on Contrast Sensitivity and / or visual acuity outcomes in one or both eyes; 11. Pupil abnormalities (non-reactive, tonic, abnormally shaped) in one or both eyes; 12. Subjects that cannot achieve a minimum pharmacologic pupilar dilatation of 5 mm in one or both eyes; 13. Complicated surgery expected; 14. Ocular surface disease (clinical symptoms) in one or both eyes; 15. Clinically significant dry eye as determined by the investigator's judgement in one or both eyes; 16. Anterior segment pathology that might increase intraoperative risk or compromise IOL stability; 17. Diabetic retinopathy; 18. Congenital ocular anomalies; 19. Chronic or recurrent inflammatory eye diseases; 20. Active infectious conjunctivitis, keratitis or uveitis in either eye within 30 days prior to surgery; 21. Subjects who may be expected to require a combined or other surgical procedure in either eye; 22. Pregnant, lactating or, if able to bear children, unwilling to use medically acceptable birth control over the course of the study; 23. Concurrent or previous (within 30 days) participation in another drug or device investigation; 24. Systemic medications that may confound the outcome or increase the risk to the subject in the opinion of the investigator (tamsulosin hydrochloride (Flomax) or other medications with similar side effects (floppy iris syndrome); 25. Subjects with conditions that increase the risk of zonular rupture during cataract extraction procedure that may affect the postoperative centration or tilt of the lens; 26. Subjects who are expected to require retinal laser treatment; 27. Patients showing contraindications as listed in the current Instructions for use (IFU); 28. Unsuitable for study participation for any other reason, as determined by Investigator's clinical judgment (reason to be documented on eCRF). In addition to above mentioned in- and exclusion criteria, subjects shall be discontinued when certain conditions are present at the time of surgery, including: * zonular instability; * need for iris manipulation; * capsular fibrosis or other opacity; and * inability to fixate IOL in desired position. In such cases, the subject shall be followed until the condition has stabilized.

Locations (8)

Univ.-Klinik fuer Augenheilkunde und Optometrie

Vienna, Austria

Gemini Eye Clinic Vyškov

Vyškov, Czechia

Gemini Eye Clinic Zlín

Zlín, Czechia

Augenklinik Ahaus

Ahaus, Germany

Outcomes

Primary Outcomes

Primary Safety Endpoint: Mean Corrected Distance Visual Acuity

The primary safety endpoint is to show that the mean monocular Corrected Distance Visual Acuity (CDVA) at at 120-180 days postoperative is statistically non-inferior to outcomes obtained in the control group using a non-inferiority margin of 0.1 logMAR, a 1-sided test and a significance level of 0.05. This analysis will be done for first implanted eyes as well as all implanted eyes per subject.

Time frame: 120-180 days postoperative

Co-Primary Safety Endpoint: Monocular Contrast Sensitivity - Between-group mean difference

The co-primary safety endpoint is to compare the outcomes on monocular contrast sensitivity under mesopic light conditions (with and without glare) between the study and the control group at 120-180 days postoperative. This analysis will be done for first implanted eyes per subject. The following Log Contrast Sensitivity Analysis will be performed: \- Between-group mean difference in log contrast sensitivity with 90% non-parametric confidence interval for each spatial frequency.

Time frame: 120-180 days postoperative

Co-Primary Safety Endpoint: Monocular Contrast Sensitivity - descriptive statistics

The co-primary safety endpoint is to compare the outcomes on monocular contrast sensitivity under mesopic light conditions (with and without glare) between the study and the control group at 120-180 days postoperative. This analysis will be done for first implanted eyes per subject. The following Log Contrast Sensitivity Analysis will be performed: \- Provide descriptive statistics for the log contrast sensitivity for each group (mean, SD, median, 0th, 25th, 50th 75th, and 100th percentiles) and for each spatial frequency.

Time frame: 120-180 days postoperative

Co-Primary Safety Endpoint: Monocular Contrast Sensitivity - frequency with glare

The co-primary safety endpoint is to compare the outcomes on monocular contrast sensitivity under mesopic light conditions with glare between the study and the control group at 120-180 days postoperative. This analysis will be done for first implanted eyes per subject. The following Log Contrast Sensitivity Analysis will be performed: \- The percentage of eyes that can and cannot see the reference pattern for each spatial frequency.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Clinical Study to Evaluate Clinical Outcomes of LuxSmart IOL as Compared With LuxGood IOL

Overview

Conditions

Interventions

Eligibility

Locations (8)

Outcomes

Primary Outcomes

Secondary Outcomes